Competitors of British animal health products supplier Dechra Pharmaceuticals are not expected to oppose a planned takeover of the company by a consortium led by Swedish private equity firm EQT, a Brussels-based antitrust lawyer who …
Jonathan Milner, founder of British protein research tools provider Abcam, is considering a number of paths to gain back control of the company after voicing his opposition to a $24-per-share offer the target received from …
Abcam founder reviewing options to regain company control Read More »
The EQT-led consortium planning to acquire British animal health company Dechra Pharmaceuticals should file a formal merger notification with the European Commission (EC) within the next few weeks, EU competition lawyers familiar with the deal …
EQT-led consortium expected to submit EC filing for Dechra takeover within coming weeks Read More »
Pfizer’s planned US$43bn takeover of US cancer specialist Seagen is not expected to fuel strong opposition from competitors of the merging parties, although the deal is still likely to be closely scrutinised by the European …
Industry peers unlikely to oppose Pfizer/Seagen merger before EU regulator Read More »
UK-based protein research tools company Abcam has attracted interest from “pure-play” lab tools providers, as well as pharma companies with a broader offering, a person briefed on the process told Equity Report. Last month, the …
Merger control reviews by China’s State Administration for Market Regulation (SAMR) are facing significant delays, even under the fast-track procedure, partly due to the recent amendments to China’s Anti-Monopoly Law, local antitrust lawyers told Equ… …
By proposing three alternative candidates for election to the nine-member board of directors of US life science company Illumina, shareholder Carl Icahn has launched a “referendum” on the company’s direction, a US lawyer with expertise …
The European Court of Justice (ECJ) is unlikely to uphold the appeal of US life science company Illumina against the EU’s General Court ruling not to annul the European Commission (EC)’s decision to review its …
Illumina’s appeal against EC review of merger with Grail likely to fail, lawyers say Read More »
UK-based activist investor Bluebell Capital Partners is engaged in discussions with German pharmaceutical and biotechnology company Bayer, with the dialogue revolving around a potential separation of the group’s pharma and crop science businesses, as… To …
Activist investor Bluebell Capital Partners in talks with Bayer management Read More »
Planned changes to India’s competition laws will place a burden on both the merging parties and the regulator to gather all the relevant documentation within a reduced time frame, with M&A deals in the technology, …
India’s competition law reform likely to increase pressure on merging parties Read More »
Valeria is a seasoned business and financial journalist with fifteen years of industry experience.
Before launching Equity Report in October 2022, Valeria was European Editor for US-based financial news service CTFN, where she spent seven years reporting on event-driven situations, breaking news stories on complex financial and regulatory issues across several jurisdictions, from Europe and Africa to China, India, Brazil, and Australia.
Prior to that, she was Senior Reporter at TelecomFinance, Middle East correspondent, and later Southern Europe correspondent at Mergermarket (currently ION), and held a number of editorial positions with Dubai and London-based b2b publications.
She holds a BA (Hons) in Languages and Public Relations from Leeds Beckett University and an MA in International Journalism from University of Central Lancashire.
